)
Edge15 May 2026
TOMRA: Closing the Loop
The story of TOMRA: from reverse vending machine pioneer to global technology for deposit systems, recycling, and resource optimization.
Sprint Bioscience
Sprint Bioscience (SPRINT) investor relations material
Sprint Bioscience Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary13 May, 2026
Executive summary
Achieved significant progress in R&D programs, expanding medical and commercial value of the portfolio and strengthening financial and operational position.
Positive preclinical proof-of-concept data in VRK1 and NNMT programs, with NNMT now targeting chronic kidney disease in addition to solid tumors.
DCPS program advanced with new research supporting its use in AML, and STK25 program maintained focus on MASH after strategic review.
Established a revolving credit facility, improving capital structure and financial flexibility.
Financial highlights
Net sales for Q1 2026 were 0 MSEK, down from 14.1 MSEK in Q1 2025.
Operating result for Q1 2026 was -14.3 MSEK, compared to -5.0 MSEK in Q1 2025.
Net result after tax for Q1 2026 was -12.9 MSEK, versus -5.6 MSEK in Q1 2025.
Cash flow from operations was -19.3 MSEK, with cash and equivalents at quarter-end of 108.3 MSEK (18.8 MSEK in Q1 2025).
Number of shares outstanding at quarter-end: 105,515,538; market capitalization: 251 MSEK.
Outlook and guidance
No formal forecast provided for future periods.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sprint Bioscience
- Record revenue and profit growth fueled by a major asset sale and portfolio optimization.SPRINT
Q4 202511 Feb 2026 - TREX1 program sold to Gilead for $14M upfront, boosting financials after a loss-making quarter.SPRINTQ3 202525 Nov 2025
- Early-stage drug discovery innovator leverages partnerships and a broad portfolio for growth.SPRINTLife Science Summit 202519 Nov 2025
- Rights issue completed, VRK1 returned, revenue down, new EDDC partnership for MASH.SPRINTQ2 202527 Aug 2025
- Revenue declined and losses widened in Q3, with significant financing uncertainty ahead.SPRINTQ3 202413 Jun 2025
- Net sales rose sharply and losses narrowed as research milestones and industry interest increased.SPRINTQ2 202413 Jun 2025
- Lower Q1 revenue, cost cuts, and capital raise as VRK1 returns and Petra01 is discontinued.SPRINTQ1 20256 Jun 2025
- Revenue up, losses widen, new AML program launched, funding risk persists.SPRINTQ4 20245 Jun 2025
Next Sprint Bioscience earnings date
Q2 202626 Aug, 2026
Sprint Bioscience
Next Sprint Bioscience earnings date
Q2 202626 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage